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Summary The expression of epidermal growth factor receptor (EGF-R) in 34 formalin fixed paraffin
embedded specimens of malignant mesothelioma was examined using the F4 antibody. Eight samples of
reactive pleura showed homogenous cytoplasmic staining with the antibody. EGF-R positive cells (> 5%)
were found in 68% of the mesotheliomas examined. EGF-R positivity was more commonly seen in the
epithelial histological subtype than in the sarcomatous or mixed subtypes. Patients with <5% of
mesothelioma cells staining positive for EGF-R had a significantly shorter survival (median 299 days)
compared with patients whose tumours had a greater number of cells positive for EGF-R (median 446 days)
(P = 0.04). However, when the histological subgroup was also taken into consideration (epithelial type had a
significantly longer survival than the sarcomatous or mixed) the survival difference in relation to EGF-R
positivity was no longer significant (P = 0.08). EGF-R could not be used to distinguish between malignant and
benign mesothelial tissue and was not an independent prognostic factor for survival.
There has been a four-fold increase in deaths from
mesothelioma over the period 1967 to 1984 (Jones &
Thomas, 1986). In 1986 there were 695 deaths from the
disease and given the strong relationship with asbestos
exposure it is highly likely that the death rate will continue to
increase over the next decade (Britton, 1989).
Three different histological subtypes of mesothelioma can
be identified: the epithelial, sarcomatous and mixed cell type.
Published data show an advantage for survival in patients
with the epithelial subtype of mesothelima compared with
patients with mixed or purely sarcomatous cell types
(Wanebo et al., 1976; Griffiths et al., 1980; Antman et al.,
1981; Law et al., 1982; Chahinian et al., 1982; Hillerdal,
1983; Martensson et al., 1984).
Epidermal growth factor (EGF) is a small polypeptide with
diverse effects on growth characteristics of cell lines, it is
known also to enhance the growth of epithelial cells in vivo.
(Cohen et al., 1982; Gusterson et al., 1984; Ozanne et al.,
1986). The effect of the growth factor is mediated by the
specific receptor and epidermal factor receptor (EGF-R) is
expressed in a variety of normal cells of non-haematological
origin and overexpression is seen in some malignancies. In
bladder and breast carcinoma overexpression of EGF-R had
clinical importance (Neal et al., 1985; Sainsbury et al., 1987).
The F4 antibody is a monoclonal mouse antibody of the
IgGI subclass and is directed to the cytoplasmic domain of
the EGF-R. The monoclonal antibody was produced to a
synthetic peptide consisting of residues 985-996 from the
complete EGF-R sequence of 1,206 amino acids (Gullick et
al., 1986). The F4 antibody is capable of identifying the
receptor using paraffin embedded specimens (Berger et al.,
1987).
The aim of the present study was to investigate the expres-
sion of EGF-R in benign and malignant mesothelium and to
examine the staining patterns with1in different histological
subgroups of malignant mesothelioma. The expression of
EGF-R as a prognostic factor in malignant pleural
mesothelioma was also analysed.
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Materials and methods
Representative paraffin embedded specimens obtained during
thoracotomy from 34 patients between 1982 and 1986 were
used as source material. A further eight patients samples,
with reactive mesothelial proliferation due to
pneumothoraces, were also studied. All samples were fixed in
10% formol saline. After routine haemotoxylin and eosin
preparations additional staining was performed which
included diastase/alcian blue/periodic acid Schiff, carcinoem-
bryonic antigen and CAM 5.2 (a cytokeratin marker). In
some cases additional ultrastructural confirmation of
mesothelioma was performed.
From each patient's tumour, 51L sections were cut and
dewaxed in Xylene for 10 min followed by rehydration in
decreasing concentrations of alcohol (100%, 95%, 90% and
75% respectively) and water, and finally washed in Tris
buffered saline (TBS) 0.5 M at pH 7.6. The sections were
pre-incubated for 10 min with normal rabbit immunoglobulin
serum (Dakopatts, Denmark) diluted in TBS 1:5. The excess
was washed off in TBS for 5 min. Then the sections were
covered with the monoclonal antibody, F4, at' a concentra-
tion of 1:50 in diluted normal rabbit immunoglobulin and
incubated overnight at 4°C. Subsequent layers consisted of a
rabbit anti-mouse immunoglobulin Z259 (Dakopatts) at a
concentration of 1:25 in diluted normal rabbit serum for
30 min at room temperature and excess washed off in TBS
for 5 min. The sections were then immediately incubated with
monoclonal mouse APAAP D651 (Dakopatts) also at a con-
centration of 1:25 in diluted rabbit serum for 30 min at room
temperature and excess washed off in TBS for 5 min. To
increase the intensity of staining the last two steps were
repeated. Finally, the red enzyme reaction was developed
with Naphthol AS Biphosphate and Fast Red in
TBS 0.1 M pH 8.2 with 1 mM levamisole to block endogenous
alkaline phosphatase. The sections were then incubated for
20 min at room temperature. Finally the sections were
washed in TBS and water and counterstained in haematox-
ylin and eosin for 5 min. For control, two sections of normal
skin were used in each batch stained. One of the sections was
incubated with the F4 as the positive control and for
negative control the other was incubated with non-specific
immunoglobulin. Otherwise the control sections were pro-
cessed as described above. Inter and intra assay consistency
was monitored by the inclusion of the two control sections of
normal skin. Any assay in which either control was unsatis-
factory was repeated.
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After scanning on low power, twenty high power fields
(x 10 eyepiece, x 40 objective) of the tumour and reactive
mesothelium were examined. The number of positively
stained cells (but not the intensity of staining) was estimated.
Results were expressed as four groups, e.g. EGF-R -ve
(0-4%), EGF-R + ve (5-19%), EGF-R + + ve (20-50%)
and EGF-R + + + ve (>50%).
Statistical methods
Contingency tables were analysed using Fisher's exact test.
The patients survival was displayed using Kaplan Meier
plots. Differences in survival were determined using log rank
analysis.
Results
Thirty-four specimens from patients with malignant
mesothelioma and eight specimens of reactive pleura were
studied. The median age for the mesothelioma patients was
61 years (range 36-78). There were 29 male and five female
patients with mesothelioma. Sixteen mesotheliomas were
epithelial, nine sarcomatous and nine mixed cell type.
When the reactive pleura was examined the mesothelial
cells showed homogenous cytoplasmic staining. Fibroblasts
stained less intensely, endothelial cells, smooth muscle cells,
adventitia, adipocytes were weakly positive for EGF-R.
In epithelial mesotheliomas there was often diffuse but
inhomogeneous staining (Figure 1) of epithelial tumour cell
cytoplasm with no nuclear staining. Little background stain-
ing was seen. In fibroblastic mesotheliomas, perinuclear
cytoplasmic positive stippled foci were present. Not all
tumour cells were positive. Muscle gave positive background
staining. Weak background staining of bronchial and bron-
chiolar epithelium, mucous glands and nerves was seen.
EGF-R positivity (.> 5%) was found in 68% of the
mesotheliomas examined. In 41% of these mesotheliomas
more than half of the cells were EGF-R positive (see Table
I). The EGF-R staining varied (P = 0.003) between the three
histological subgroups, EGF-R positivity being commonest
in epithelial mesothelioma (see Table I).
Survival data were available on all 34 mesothelioma
patients. The survival was compared for the proportion of
cells staining for EGF-R. Patients with <5% EGF-R
positive tumours had a significantly shorter survival (median
299 days) compared with tumours in which ) 5% of cells
stained for EGF-R receptor, median 446, P = 0.04 (Figure
2). There are four patients alive at (15,18,33,85 months) in
the EGF-R (<5%) group out of 23 patients and one patient
alive at 13 months out of 11 in the higher positively EGF-R
group. The survival for patients with EGF-R positive
tumours staining for 5-19% of cells, 20-50% and >50% of
cells was not statistically different (P>0.05). There was also
a survival difference between the three main histological sub-
groups (Figure 3) (P = 0.05). When the histological sub-
groups was taken into consideration, the survival difference
according to EGF-positivity was no longer statistically
significant (P = 0.08).
Table I EGF-R positive cells and histology
% ofcells staining EGF-R positive
Histology <5% 5-19% 20-50% >50%
Epithelial 2 3 1 10
Sarcomatous 2 3 1 3
Mixed 7 - 1 1
Total 11(32%) 6(18%) 3(9%) 14(41%)
Statistical analysis performed on differences between the <5%
EGF-R positive groupand the other three groupscombined, P = 0.003
Fisher's exact test.
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Discussion
Epidermal growth factor is found in many benign and malig-
nant tissues. In malignant pleural mesothelioma a variable
number of cells positive for EGF-R were found. EGF-R
positivity was significantly related to different histological
subgroups of mesothelioma. Epithelial tumours had a much
higher proportion of cells positive for EGF-R compared with
for example the mixed histology subgroup where more
tumours had a very low level of expression. In benign reac-
tive pleura, both mesothelial cells and fibroblasts were
positive for EGF-R, and this confirms previous observations
that EGF-R is present on normal proliferating and non-
proliferating cells. The expression of EGF-R therefore does
not necessarily provide information about the proliferative
state of cells and not all cells positive for EGF-R are
biologically responsive to the growth factor (Carpenter &
Zendegui, 1986). Expression of EGF-R in some tissues could
therefore be related to specific stages of differentiation rather
than malignant transformation. The presence of EGF-R on
the cell surface of ectodermal and mesenchymal cells of
reactive pleura did not indicate whether malignant
mesothelioma was derived from the epithelial or mesen-
chymal germ layer. Indeed, fibroblasts showed some
positivity. EGF-R lacks specificity and the expression of the
receptor cannot be used to differentiate malignant
mesothelioma from secondary carcinoma involving the
pleura. In our own and other studies adenocarcinoma of the
lung and other non-small cell lung cancers express EGF-R
(Cerny et al., 1986; Berger et al., 1987; Dazzi et al., 1989).
Correlation between EGF-R expression, tumour invasion
and stage of bladder cancer has been described (Neal et al.,
1985) and an association with survival has been shown in
breast cancer (Sainsbury et al., 1987). In these studies
significantly more invasive bladder tumours stained positively
for the EGF-R receptor. There were also significantly more
poorly differentiated tumours staining positively. Further-
more, in the breast cancer study, the relapse-free survival and
overall survival were significantly worse for patients with
EGF-R positive tumours. These findings are contrary to the
present investigation of mesothelioma where patients with
tumours with a high proportion of EGF-R positive cells had
a better prognosis. It should be noted that in contrast to the
normal pleura, normal bladder and breast tissue are negative
for EGF-R (Neal et al., 1985; Sainsbury et al., 1987) and
therefore expression of EGF-R in cancers of breast and
bladder could be a characteristic of malignant transforma-
tion.
We conclude that EGF-R expression is not an indicator
for malignant transformation in mesothelioma but is a prog-
nostic feature for survival. However, the epithelial tumour
histological subgroup had a significantly better survival than
the mixed or sarcomatous group. The proportion of strongly
EGF-R positive tumours was also higher in the epithelial
group. Mesenchymal and epithelial cells of normal pleura
also express EGF-R and the cell of origin of the tumour
cannot be identified by the presence of EGF-R, nor can the
presence of the receptor be used to assist the differential
diagnosis of mesothelioma from other types of malignancy
with pleural mestastases.
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